CN113966343A - 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 - Google Patents

结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 Download PDF

Info

Publication number
CN113966343A
CN113966343A CN202080042874.7A CN202080042874A CN113966343A CN 113966343 A CN113966343 A CN 113966343A CN 202080042874 A CN202080042874 A CN 202080042874A CN 113966343 A CN113966343 A CN 113966343A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080042874.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·基拉索斯
A·科皮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN113966343A publication Critical patent/CN113966343A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080042874.7A 2019-06-11 2020-06-10 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 Pending CN113966343A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860146P 2019-06-11 2019-06-11
US62/860,146 2019-06-11
PCT/US2020/037008 WO2020252029A1 (en) 2019-06-11 2020-06-10 Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
CN113966343A true CN113966343A (zh) 2022-01-21

Family

ID=71948699

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042874.7A Pending CN113966343A (zh) 2019-06-11 2020-06-10 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法

Country Status (17)

Country Link
US (2) US11655286B2 (https=)
EP (1) EP3983015A1 (https=)
JP (1) JP2022536469A (https=)
KR (1) KR20220019755A (https=)
CN (1) CN113966343A (https=)
AU (1) AU2020292283A1 (https=)
BR (1) BR112021023335A2 (https=)
CA (1) CA3140075A1 (https=)
CL (4) CL2021003215A1 (https=)
CO (1) CO2021015254A2 (https=)
EA (1) EA202192810A1 (https=)
IL (1) IL288727A (https=)
MA (2) MA56205A (https=)
MX (1) MX2021015156A (https=)
PH (1) PH12021552903A1 (https=)
SG (1) SG11202112462RA (https=)
WO (1) WO2020252029A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114404614A (zh) * 2022-01-28 2022-04-29 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
WO2023236041A1 (zh) * 2022-06-07 2023-12-14 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN118440191A (zh) * 2024-05-11 2024-08-06 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用
CN118530352A (zh) * 2024-05-11 2024-08-23 重庆原伦生物科技有限公司 一种特异性识别假单胞菌PcrV的抗体及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
FR3114970B1 (fr) 2020-10-08 2023-06-30 Univ Tours Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires
WO2024206669A2 (en) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Antibodies for targeting cd47 and b7h3 and methods of use thereof
AU2024307442A1 (en) 2023-06-28 2026-02-19 Universität Zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910197A (zh) * 2007-11-30 2010-12-08 卡罗拜奥斯制药公司 针对铜绿假单胞菌pcrv抗原的抗体
EP2407537A1 (en) * 2009-03-11 2012-01-18 Shionogi & Co., Ltd. Humanized pcrv antibody having anti-pseudomonal activity
WO2014074528A2 (en) * 2012-11-06 2014-05-15 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
CN104136042A (zh) * 2011-11-07 2014-11-05 米迪缪尼有限公司 使用抗假单胞菌Psl和PcrV结合分子的联合治疗
WO2017095744A1 (en) * 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002064161A2 (en) 2001-01-26 2002-08-22 Mcw Research Foundation, Inc. Method and compositions for immunization with the pseudomonas v antigen
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
EA020544B1 (ru) 2008-01-10 2014-12-30 Шионоги Энд Ко., Лтд. АНТИТЕЛА ПРОТИВ PcrV
BRPI0906945A2 (pt) 2008-01-11 2015-07-14 Lilly Co Eli (e)-n-{3-[1-(8-flúor-11h-10-oxa-1-aza-dibenzo[a,d]ciclo-h epten-5-ilideno)-propil]-fenil}-metinsulfona amida como modulador de receptores de glicocorticoides para o tratamento de reumatoide.
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2012122533A2 (en) 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
CA3076632A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910197A (zh) * 2007-11-30 2010-12-08 卡罗拜奥斯制药公司 针对铜绿假单胞菌pcrv抗原的抗体
EP2407537A1 (en) * 2009-03-11 2012-01-18 Shionogi & Co., Ltd. Humanized pcrv antibody having anti-pseudomonal activity
CN102341496A (zh) * 2009-03-11 2012-02-01 盐野义制药株式会社 具有抗绿脓杆菌作用的人源化PcrV抗体
CN104136042A (zh) * 2011-11-07 2014-11-05 米迪缪尼有限公司 使用抗假单胞菌Psl和PcrV结合分子的联合治疗
WO2014074528A2 (en) * 2012-11-06 2014-05-15 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
CN104995209A (zh) * 2012-11-06 2015-10-21 米迪缪尼有限公司 使用抗假单胞菌Psl和PcrV结合分子的联合治疗
WO2017095744A1 (en) * 2015-11-30 2017-06-08 Medimmune, Llc Method for preventing or treating nosocomial pneumonia

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114404614A (zh) * 2022-01-28 2022-04-29 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
CN114404614B (zh) * 2022-01-28 2024-04-23 上海交通大学 一种靶向铜绿假单胞菌的免疫脂质体及其制备方法和应用
WO2023236041A1 (zh) * 2022-06-07 2023-12-14 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN118440191A (zh) * 2024-05-11 2024-08-06 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用
CN118530352A (zh) * 2024-05-11 2024-08-23 重庆原伦生物科技有限公司 一种特异性识别假单胞菌PcrV的抗体及其应用
CN118440191B (zh) * 2024-05-11 2025-06-10 重庆原伦生物科技有限公司 一种抗铜绿假单胞菌PcrV抗体的制备及其应用

Also Published As

Publication number Publication date
IL288727A (en) 2022-02-01
CL2023003695A1 (es) 2024-06-14
EP3983015A1 (en) 2022-04-20
CO2021015254A2 (es) 2021-11-19
CL2023003696A1 (es) 2024-06-14
CL2023003694A1 (es) 2024-06-14
JP2022536469A (ja) 2022-08-17
US20200392210A1 (en) 2020-12-17
MA54975A1 (fr) 2022-05-31
MA56205A (fr) 2022-04-20
US11655286B2 (en) 2023-05-23
PH12021552903A1 (en) 2022-04-04
BR112021023335A2 (pt) 2022-01-04
KR20220019755A (ko) 2022-02-17
US12552856B2 (en) 2026-02-17
MX2021015156A (es) 2022-01-18
US20230322907A1 (en) 2023-10-12
CL2021003215A1 (es) 2022-09-30
WO2020252029A1 (en) 2020-12-17
MA54975B1 (fr) 2023-08-31
AU2020292283A1 (en) 2021-12-23
SG11202112462RA (en) 2021-12-30
CA3140075A1 (en) 2020-12-17
EA202192810A1 (ru) 2022-03-05

Similar Documents

Publication Publication Date Title
JP7500812B2 (ja) 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体
US11571482B2 (en) Human antibodies to S. aureus Hemolysin A toxin
US20230192831A1 (en) Human Antibodies to GREM1
US12552856B2 (en) Anti-PCRV antibodies that bind PCRV, compositions comprising anti-PCRV antibodies, and methods of use thereof
KR102667023B1 (ko) 항-c5 항체 및 이의 용도
KR20200058525A (ko) 스타필로코커스 표적 항원 및 보체 성분에 결합하는 이특이적 항원-결합 분자 및 이의 용도
EA047177B1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2964670B1 (en) Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
EA041355B1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА К ТОКСИНУ ГЕМОЛИЗИНУ А S.aureus
NZ795857A (en) Human antibodies to S. aureus Hemolysin A toxin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220121

WD01 Invention patent application deemed withdrawn after publication